Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia DOI Open Access
Nam Xuan Vo,

Huong Lai Pham,

Thị Hồng Châu Bùi

et al.

Healthcare, Journal Year: 2024, Volume and Issue: 13(1), P. 59 - 59

Published: Dec. 31, 2024

Objectives: Dyslipidemia, a significant risk factor for cardiovascular disease (CVD), is marked by abnormal lipid levels, such as the elevated lowering of low-density lipoprotein cholesterol (LDL-C). Statins are first-line treatment LDL-C reduction. Pitavastatin (PIT) has shown potential in and improving high-density (HDL-C). This review assesses pitavastatin’s efficacy, effectiveness, safety dyslipidemia management Asia. Methods: A systematic was conducted using PubMed, Cochrane, Embase databases up to November 2024, adhering Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. Seventeen studies (12 RCTs 5 non-RCTs) were analyzed, focusing on reduction, profiles, adverse events. The quality assessed checklists ensure selection best limit bias. Results: doses (1–4 mg) reduced 28–47%, comparable atorvastatin, rosuvastatin, simvastatin. 2 mg dose matched atorvastatin’s 10 efficacy both short-term (35–42%) long-term (28–36%) use. target achievement rates 75–95%. Adverse events, including mild myalgia liver enzymes, rare, discontinuation low. Conclusions: an effective safe alternative traditional statins Further research outcomes high-risk groups warranted.

Language: Английский

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels DOI Creative Commons
Bożena Sosnowska, Janina Stępińska, Przemysław Mitkowski

et al.

Archives of Medical Science, Journal Year: 2024, Volume and Issue: 20(1), P. 8 - 27

Published: Jan. 30, 2024

Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and specific apolipoprotein(a). The blood concentration Lp(a) approximately 90% genetically determined, the main genetic factor determining levels size apo(a) isoform, which determined by number KIV2 domain repeats. isoform inversely proportional to Lp(a). strong independent cardiovascular risk factor. Elevated ≥ 50 mg/dl (≥ 125 nmol/l) are estimated occur in more than 1.5 billion people worldwide. However, determination performed far too rarely, including Poland, where, fact, it only since 2021 guidelines Polish Lipid Association (PoLA) five other scientific societies that measurements have begun be performed. Determination concentrations not easy due to, among things, different sizes isoforms; however, currently available certified tests make possible distinguish between with low high degree precision. In 2022, first for management patients elevated lipoprotein(a) were published European Atherosclerosis Society (EAS) American Heart (AHA). result work experts from two their aim provide clear, practical recommendations levels.

Language: Английский

Citations

19
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP) DOI Creative Commons
Maciej Banach,

Željko Reiner,

Stanisław Surma

et al.

Drugs, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity mortality across Europe. Fortunately, as much two thirds of this disease's burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines based on the sound premise that, with respect low-density lipoprotein cholesterol (LDL-C), "lower better for longer", recent data have strongly emphasised need also "the earlier better". In addition statins, which been available several decades, ezetimibe, bempedoic acid (also fixed dose combinations), modulators proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors inclisiran) additionally very effective approaches LLT, especially those at high extremely risk. real life, however, clinical practice goals still not met a proportion patients (even 70%). However, options we available, should render lipid disorders rare disease. April 2021, International Lipid Expert Panel (ILEP) published its first position paper optimal use LLT post-ACS patients, complemented existing management lipids following ACS, defined group "extremely high-risk" individuals outlined scenarios where upfront combination be considered improve access adherence and, consequently, therapy's effectiveness. These updated recommendations build previous work, considering developments evidential underpinning ongoing education role disorder therapy, changes availability drugs. Our aim provide guide address unmet need, clear practical advice, whilst acknowledging patient-centred care, accounting often large differences LLTs between countries.

Language: Английский

Citations

9
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon? DOI Creative Commons
Stanisław Surma, Amirhossein Sahebkar, Maciej Banach

et al.

Current Atherosclerosis Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 2, 2024

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of premature death. Lipid disorders, particularly elevated serum low-density lipoprotein cholesterol (LDL-C), contribute significantly to ASCVD. The risk developing ASCVD influenced by the duration exposure LDL-C concentrations (cholesterol-years concept). Implementing lipid-lowering treatments based on principles "the earlier better," lower and longer better" has been shown reduce extend lifespan. Despite availability numerous drugs, achieving satisfactory control lipid disorders remains very challenging. Therefore, there need for novel approaches improve treatment adherence.

Language: Английский

Citations

6
Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS) - study design and methodology. DOI Creative Commons
Maciej Banach, Martyna Fronczek, Tadeusz Osadnik

et al.

Archives of Medical Science, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 8, 2024

Introduction Classical risk factors such as hypertension, hypercholesterolemia, pre-diabetes, diabetes and obesity can predict adverse cardiovascular events, but they are less prognostic in patients age <60 years. Polygenic scores (PRS) be effective predicting coronary events younger middle-aged patients. Our main aim is to assess the utility of new PRS created for Polish population mortality during an 8-year follow-up a nationwide LIPIDOGEN2015 population. Material methods All DNA samples 1779 were genotyped using Infinium Global Screening Array-24+ v3.0 Kit microarrays. The amplified, fragmented, hybridized BeadChips. BeadChips scanned iScan converted genotypes Genome Studio 2.0. Results We will develop based on marked single nucleotide polymorphisms (SNPs) project's studied determine analyzed group's death due diseases (CVD) data obtained from 8-years patient-follow-up. Based developed scale biochemical analyses, we effectiveness lipid-lowering therapy with statins high low genetic sudden CVD (secondary endpoints). Conclusions scale, combined clinical covariates, facilitate creation algorithm long-term mortality. This enable us stratify more precisely, which may result earlier implementation lifestyle changes dietary adjustments potentially initiate pharmacotherapy at-risk individuals.

Language: Английский

Citations

0
Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia DOI Open Access
Nam Xuan Vo,

Huong Lai Pham,

Thị Hồng Châu Bùi

et al.

Healthcare, Journal Year: 2024, Volume and Issue: 13(1), P. 59 - 59

Published: Dec. 31, 2024

Objectives: Dyslipidemia, a significant risk factor for cardiovascular disease (CVD), is marked by abnormal lipid levels, such as the elevated lowering of low-density lipoprotein cholesterol (LDL-C). Statins are first-line treatment LDL-C reduction. Pitavastatin (PIT) has shown potential in and improving high-density (HDL-C). This review assesses pitavastatin’s efficacy, effectiveness, safety dyslipidemia management Asia. Methods: A systematic was conducted using PubMed, Cochrane, Embase databases up to November 2024, adhering Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. Seventeen studies (12 RCTs 5 non-RCTs) were analyzed, focusing on reduction, profiles, adverse events. The quality assessed checklists ensure selection best limit bias. Results: doses (1–4 mg) reduced 28–47%, comparable atorvastatin, rosuvastatin, simvastatin. 2 mg dose matched atorvastatin’s 10 efficacy both short-term (35–42%) long-term (28–36%) use. target achievement rates 75–95%. Adverse events, including mild myalgia liver enzymes, rare, discontinuation low. Conclusions: an effective safe alternative traditional statins Further research outcomes high-risk groups warranted.

Language: Английский

Citations

0